HUNT VALLEY, Md.--(BUSINESS WIRE)--Pharmaceutics International, Inc. (Pii), a leading contract development and manufacturing organization (CDMO), has announced a significant expansion of its prefilled syringe (PFS) capabilities with a $3.6 million investment in advanced labeling, fill/finish, and automated visual inspection technologies. This development reflects Pii’s commitment to supporting pharmaceutical and biotech companies with end-to-end, streamlined solutions for drug manufacturing and supply chain efficiency.
Driven by the rising demand for prefilled syringe solutions in the pharmaceutical and biotech industries, Pii’s investment includes a state-of-the-art Optima syringe labeler and Antares automated visual inspection (AVI) system. These additions enable Pii to offer integrated fill/finish and labeling services for PFS, simplifying the supply chain and reducing the time required to bring critical medicines to market.
“With this expansion, Pii strengthens its role as a comprehensive partner, allowing clients to achieve faster time-to-market by managing every step of the PFS process,” said John Fowler, Chief Executive Officer at Pii. “Our streamlined approach will support customers in optimizing both cost and quality, meeting stringent regulatory demands, and ultimately improving patient access to essential therapies.”
The Optima syringe labeler, currently being installed, will be fully operational for client use by late first half / early second half of 2025. This equipment automates essential processes, including syringe labeling, plunger insertion, and safety device integration. By combining fill/finish, automated visual inspection and labeling within Pii, customers minimize the need for multiple contract organizations, reducing logistical and regulatory complexities while streamlining product delivery timelines which is critical for time-sensitive injectables. A unified approach to fill/finish and labeling ensures rigorous quality control across all production stages, minimizing the risk of errors.
Pii’s new AVI technology from Antares, expected to be client-ready by Q3 2025, further enhances quality and compliance by automating the inspection process. This system detects particles, air bubbles, cracks, and fill-level discrepancies with unmatched precision, ensuring consistent product safety and reliability. The AVI system’s high-throughput inspection capability reduces the dependence on manual inspections and improves turnaround times for large-scale production. It also supports stringent regulatory requirements by documenting inspection data for quality analysis and traceability, crucial for FDA and other global regulatory standards.
Pii’s commitment to innovation and patient-centric solutions is central to this investment, aligning with industry trends toward self-administered therapies and ready-to-use delivery formats. By integrating advanced PFS capabilities with a comprehensive quality management system, Pii provides an efficient, reliable manufacturing solution for customers, particularly small and mid-sized pharmaceutical companies aiming for rapid clinical trials or market entry.
About Pii
Pharmaceutics International, Inc. (Pii) is a leading Contract Development and Manufacturing Organization (CDMO) that provides comprehensive solutions for aseptic and oral dosage forms. Founded in 1994 by Dr. Syed Abidi, a pioneering formulation scientist, Pii has over 30 years of experience handling complex formulations, potent compounds, and controlled substances. Based in Hunt Valley, MD, Pii’s capabilities include lyophilization, high potency isolation, and robotic filling. Our expert teams ensure the highest quality and safety standards, supporting small to medium-volume projects with scalable solutions and unmatched flexibility. Committed to client-centric drug development, Pii's mission is to enhance quality of life through innovative and high-quality pharmaceuticals. Discover more about our services and how we can support your projects at www.pharm-int.com.
